The shareholders in iCoat Medical AB (publ), corporate registration number 559172‑8208 (the “Company”) are hereby convened to the annual general meeting on Wednesday 24 April 2024 at 2.00 p.m. at IVA Konferenscenter, Grev Turegatan 16, 114 46 Stockholm.
Right to participate at the annual general meeting
Shareholders who wish to participate at the annual general meeting need to:
- on Tuesday 16 April 2024, be registered in his or her own name (not nominee registered) in the share register kept by Euroclear Sweden AB, and
- notify his or her intention to attend the annual general meeting so that the notification is received by the Company no later than Thursday 18 April 2024, by email to peder.waern@icoatmedical.com.
Nominee-registered shares
Shareholders whose shares are registered in the name of a nominee must, in order to exercise the right to vote and participate in the general meeting, register their shares in their own name (so-called voting rights registration) so that the shareholder is included in the share register kept by Euroclear Sweden as per 16 April 2024. This means that such shareholders must request voting rights registration with their nominees well in advance of this date. Voting registration requested by shareholders in such time that the registration has been completed by the nominee no later than Thursday 18 April 2024 will be considered in the preparation of the share register.
Please observe that this procedure may also apply for shares that are held in a bank’s custody account and on certain Swedish investment savings accounts (ISK).
Proxy
Shareholders represented by proxy must submit a dated and signed proxy. The validity of the power of attorney may not exceed a period of five years from its issuance. The original proxy and certificate of registration and other authorisation documents should be submitted to the Company by post at the address mentioned above in due time prior to the general meeting. The Company provides a form of proxy at request and it is also available at the Company’s website, www.icoatmedical.se and the documents will also be sent to the shareholders who request this.
Number of shares and votes
At the time of this notice, the Company has 100,000 A shares and 66,082 B shares, in total 166,082 shares. Class A shares represent ten votes per share and Class B shares one vote per share, in total 1,066,082 votes.
The Company does not hold any own shares.
Proposed agenda
- Opening of the general meeting and election of the chairman of the meeting
- Preparation and approval of the voting list
- Approval of the agenda
- Election of one or two persons to approve the minutes
- Determination of whether the general meeting has been duly convened
- Report by CEO
- Submission of the annual report and the auditor’s report
- Resolutions on the income statement and balance sheet, etc.:
- adoption of the income statement and the balance sheet,
- allocation of the Company’s result pursuant to the adopted balance sheet, and
- discharge from liability for board members and the CEO
- Resolution on the remuneration to the board of directors and the auditor
- Election of board members and auditor
- Resolution on a nomination committee and instructions to the nomination committee
- Resolution on an authorisation for the board of directors to issue new shares, warrants and/or convertible instruments
- Closing of the general meeting
Main proposals for resolutions
Item 8b) – Allocation of the Company’s result pursuant to the adopted balance sheet
The board of directors proposes that no dividend is paid for the financial year 2023 and that the Company’s result be carried forward in its entirety.
Item 9 – Resolution on the renumeration to the board of directors and the auditor
The nomination committee proposes that the board of directors’ remuneration for the time until the next general meeting shall amount to SEK 200,000 to the chairperson and SEK 100,000 to each of the other board members.
The nomination committee further proposes that the remuneration to the auditor shall be paid against approved invoice.
Item 10 – Election of board members and auditor
The nomination committee proposes that the board of directors shall consist of six (6) members and that no deputy members are appointed.
The nomination committee proposes re-election of the board members Hans Larsson, Carl Bjartmar, Marianne Jensen Waern, Bo Nilsson, Bertil Villard and Martin Åmark. Further, the nomination committee proposes that Hans Larsson be re-elected as chairperson of the board of directors.
The nomination committee proposes that the registered auditing firm KPMG AB be re-elected as the Company’s auditor, with Per Hammar as the auditor in charge.
Item 11 – Resolution regarding a nomination committee and guidelines for the work of the nomination committee
For the period until the end of the next annual general meeting, the nomination committee proposes re-election of Kristina Nilsson Ekdahl, Johan Thorell, Pär Josefsson, Hans Larsson and Marianne Jensen Waern as members of the nomination committee. Johan Thorell represents the shareholder Gryningskust Holding AB and Pär Josefsson the shareholder Conspargo Capital AB. Kristina Nilsson Ekdahl and Marianne Jensen Waern are shareholders and two of the founders of the Company. Hans Larsson is a shareholder and chairperson of the board of directors.
The nomination committee proposes that the annual general meeting resolves to adopt the instructions for the work of the nomination committee set out below.
The functioning of the nomination committee
The nomination committee appoints the chairperson of the committee. The chairperson of the board of directors or another board member shall not be the chairperson of the nomination committee.
The nomination committee shall meet as often as is necessary for the nomination committee to fulfil its duties, but at least once per year. Notice convening other meetings is issued by the chairperson of the nomination committee. A meeting shall also be held if requested by a member. Minutes shall be kept at the nomination committee’s meetings.
The nomination committee is quorate if not less than two of the members are present. Resolutions of the nomination committee shall be adopted by a simple majority of the members present or, in the event of a tied vote, the chairperson shall have the casting vote.
Responsibilities of the nomination committee
The nomination committee shall prepare proposals on the following issues for resolution at the annual general meeting 2025:
- Chairman at the meeting;
- The number of directors of the board;
- Board remuneration, with a division between the chairperson and other deputies;
- Remuneration to the auditor:
- Election of board members and chairperson of the board;
- Election of auditor; and
- Election of members of the nomination committee and instructions for the nomination committee for the annual general meeting 2026.
Item 12 – Resolution on an authorisation for the board of directors to issue new shares, warrants and/or convertible instruments
The board of directors hereby proposes that the general meeting of shareholders resolves to authorise the board of directors for the period up to the next annual meeting of shareholders to resolve, whether on one or several occasions, to increase the Company’s share capital by way of issue of shares, warrants and/or convertible instruments. The board of directors shall be authorised to adopt resolutions on an issue of shares, warrants and/or convertible instruments with deviation from the shareholders’ pre-emption rights and/or an issue in kind or an issue by way of set-off.
The board of directors shall however not be authorised to adopt decisions that result in an increase of the share capital of the Company of more than sixty (60) percent in relation to the share capital of the Company at the time of this authorisation first being utilised.
An issue in accordance with this authorisation shall be on market conditions. The board of directors shall be authorised to resolve on the terms and conditions regarding issues under this authorisation and what persons shall be entitled to subscribe for the shares, warrants and/or convertible instruments. The reason to propose that the board of directors shall be authorised to resolve on an issue with deviation from the shareholders’ pre-emption rights and that the board of directors shall be authorised to resolve on an issue in kind or an issue by way of set-off is that the Company shall be able to issue shares, warrants and/or convertible instruments in order to raise capital, tie strategically important shareholders to the Company or to carry out acquisitions or strategic cooperations.
Majority requirements
Pursuant to the Swedish Companies Act, resolution in accordance with item 12 above (authorisation) require for its validity the support of shareholders with at least two-thirds (2/3) of both the votes cast and the shares represented at the meeting.
Questions to the board of directors and the CEO
The board of directors and the CEO shall, upon request by any shareholder, and where the board of directors deems that the information can be provided without significant harm to the Company, provide information in respect of any circumstances which may affect the assessment of a matter on the agenda or the Company’s financial position. Questions may be submitted in advance via email to peder.waern@icoatmedical.com.
Provision of documents
The annual report and the auditor’s report and all other documents pursuant to the Swedish Companies Act will be available at the Company’s office and the Company’s website, www.icoatmedical.se no later than 3 April 2024. The documents will be sent free of charge to the shareholders who request this and state their address.
In connection with the general meeting personal data will be processed in accordance with Euroclear’s privacy policy, which is available at Euroclear’s website https://www.euroclear.com/
_____________________
Stockholm in March 2024
iCoat Medical AB (publ)
The board of directors
Please note that the English version of this document is a translation which has been made for convenience purposes only. In case of inconsistencies between the translated English version and the official Swedish version, the Swedish version will prevail.